457 filings
Page 5 of 23
4
c45ai
4 Apr 23
Replimune / Tanya Lewis ownership change
8:01pm
4
4k4mld5k8248
4 Apr 23
Replimune / Sushil Patel ownership change
8:01pm
4
oa5mkd2t90rrzo xgm4
4 Apr 23
Replimune / Robert Coffin ownership change
8:00pm
4
3ral3l501082j 982
4 Apr 23
Replimune / Philip Astley-Sparke ownership change
8:00pm
8-K
bb0wwlr5qzvbx
27 Feb 23
Regulation FD Disclosure
8:49am
SC 13G/A
arrf2aac8d7cj
14 Feb 23
Replimune / Redmile ownership change
4:22pm
SC 13G
q17ib469w09w
14 Feb 23
Replimune / BAKER BROS. ADVISORS ownership change
4:00pm
SC 13G/A
4pnr974eb3j4 u5he
14 Feb 23
Replimune / PRICE T ROWE ASSOCIATES ownership change
12:38pm
SC 13G/A
48vnf
13 Feb 23
Replimune / Omega Fund IV ownership change
4:49pm
8-K
5js1wz sin
9 Feb 23
Replimune Reports Fiscal Third Quarter Financial Results and Provides Corporate Update
8:15am
SC 13G
ovta37pjf
3 Feb 23
Replimune / BlackRock ownership change
12:10pm
8-K
ckty5jdtc72a5m1
4 Jan 23
Replimune Appoints Former Sanofi U.S. Commercial Oncology Head, Chris Sarchi, as Chief Commercial Officer and Sushil Patel as Chief Strategy Officer
9:15am
4
jd5 msh0hnxcgx79k6r
13 Dec 22
Replimune / Pamela Esposito ownership change
8:01pm
8-K
l711 nvb4
12 Dec 22
Replimune Announces Proposed Public Offering
5:00pm
424B5
pwzhl5a
12 Dec 22
Prospectus supplement for primary offering
6:03am
424B5
sejtk us5719xt
7 Dec 22
Prospectus supplement for primary offering
4:58pm
8-K
u1tz8m pf7xfwks
7 Dec 22
Replimune Enters into Clinical Collaboration Agreement with Roche for the Development of RP3 In Colorectal Cancer and Hepatocellular Carcinoma
7:15am
SC 13D/A
wpk n00pm
6 Dec 22
Replimune / Atlas Venture Fund X ownership change
5:00pm
4
6xw 25y25e
5 Dec 22
Replimune / Konstantinos Xynos ownership change
8:01pm